They set an “underweight” rating and a $16.00 price target on the stock. 1/11/2016 – Novocure had its “outperform” rating reaffirmed by analysts at Wedbush.
They set an “underweight” rating and a $16.00 price target on the stock. 1/11/2016 – Novocure had its “outperform” rating reaffirmed by analysts at Wedbush.